Safety and efficacy of oncolytic HSV-1 G207 inoculated into the cerebellum of mice.

ABSTRACT: Primary malignant central nervous system (CNS) tumors are the leading cause of childhood cancer-related death and morbidity. While advances in surgery, radiation, and chemotherapy have improved the survival rates in children with malignant brain tumors, mortality persists in certain subpopulations and current therapies are associated with extreme morbidity. This is especially true for children with malignant infratentorial tumors. Accordingly, G207, a genetically engineered herpes simplex virus (HSV-1) capable of selectively targeting cancer cells has emerged as a promising therapeutic option for this patient population. Herein, we demonstrate that cerebellar inoculation of G207 was systemically non-toxic in an immunocompetent, HSV-1 sensitive mouse strain (CBA/J). Mice had neither abnorma

SUBMITTER: Bernstock JD 

PROVIDER: S-EPMC7416750 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature